Cargando…
Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study
BACKGROUND: There is heterogeneity in the clinical manifestations and responses to drugs in RA patients due to variety of factors such as genes and environment. Despite advances in the treatment of rheumatoid arthritis (RA), approximately 40% of RA patients still do not achieve primary clinical outc...
Autores principales: | Mu, Rong, Li, Chun, Li, Xiaomei, Ke, Yao, Zhao, Ling, Chen, Lin, Wu, Rui, Wu, Zhenbiao, Zuo, Xiaoxia, Xie, Yanli, Chen, Jinwei, Wei, Wei, Liu, Yi, Li, Zhijun, Dai, Lie, Sun, Lingyun, Liu, Xiangyuan, Li, Zhanguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315426/ https://www.ncbi.nlm.nih.gov/pubmed/34327344 http://dx.doi.org/10.1016/j.lanwpc.2021.100128 |
Ejemplares similares
-
Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013) -
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020) -
Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020) -
Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
por: Deng, Li, et al.
Publicado: (2022) -
Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway
por: Liu, Sha, et al.
Publicado: (2021)